Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000535454 | SCV000654341 | likely benign | Developmental and epileptic encephalopathy 94 | 2024-01-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002330960 | SCV002628373 | uncertain significance | Inborn genetic diseases | 2019-03-12 | criteria provided, single submitter | clinical testing | The p.K1389Q variant (also known as c.4165A>C), located in coding exon 32 of the CHD2 gene, results from an A to C substitution at nucleotide position 4165. The lysine at codon 1389 is replaced by glutamine, an amino acid with some similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |